Cibus, Inc., a biotechnology company specializing in agricultural gene editing, reported a net loss of $132.2 million for the fiscal year ending December 31, 2025, a significant reduction from the $282.7 million loss recorded in 2024. The company's revenue for 2025 was $3.6 million, down 15% from $4.3 million in the previous year, primarily due to decreased collaboration revenues related to its Rice and Sustainable Ingredients projects. Cibus has accumulated a deficit of $858.3 million since its inception, and it anticipates continued losses as it invests in research and development (R&D) to advance its product pipeline.
In 2025, Cibus implemented a series of cost-cutting measures, including workforce reductions that resulted in a decrease in R&D expenses to $44.2 million, down 12% from $50.4 million in 2024. Selling, general, and administrative expenses also fell by 13% to $26.9 million. The company’s goodwill impairment decreased significantly to $21.0 million from $181.4 million in 2024, reflecting a reassessment of its asset values in light of stock price fluctuations. Additionally, Cibus recognized a $9.1 million impairment related to long-lived assets as it began winding down operations at its Roseville, Minnesota facility.
Cibus is focusing on its core business of developing productivity traits for major crops, particularly Rice herbicide tolerance traits, which it estimates could generate over $200 million in potential annual royalties upon full commercialization. The company is also exploring sustainable ingredient opportunities, including biofragrance products, which are partially funded through partnerships. As of December 31, 2025, Cibus had 118 full-time employees, with a significant portion dedicated to R&D efforts.
Looking ahead, Cibus faces challenges in securing additional financing to support its operations, as it had only $9.9 million in cash and cash equivalents against current liabilities of $16.9 million. The company has indicated that it will need to raise additional capital to continue its operations and meet its financial obligations. Cibus is pursuing various strategic alternatives, including potential equity or debt financing, to enhance its liquidity and support its business objectives. The company’s ability to continue as a going concern is contingent upon its success in these efforts, as it expects to incur significant expenses and operating losses in the near term.
About Cibus, Inc.
Cibus is an agricultural biotechnology company specializing in gene editing to develop plant traits that enhance crop productivity, sustainability, and environmental resilience. Its proprietary Rapid Trait Development System (RTDS) enables rapid, precise editing of elite germplasm across crops like canola, rice, and soybean. The company partners with seed companies, licensing traits for commercial use, and aims to accelerate crop breeding while reducing reliance on GMO technologies.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.